Cardiovascular Diseases in Elderly Asthma

September 26, 2021 updated by: Seoul National University Hospital

Discovering Risk Factors for Cardiovascular Diseases in Elderly Asthma

This study is a cross-sectional study to evaluate the relationship between coronary calcium score and clinical parameters of asthma such as onset of disease, lung function parameter and airway inflammation parameter (sputum eosinophil or FeNO) in Korean elderly asthma (regardless of whether they have concomittent COPD or not) patients

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Subjects who visited Allergy Clinic in SMG-SNU Boramae Medical Center for asthma or ACO will be recruited consecutively. Subjects who meets the inclusion criteria and agree to participate in the study will take coronary artery calcium scoring CT and asthma CT (inspiration and expiration images). The correlation between the degree of coronary calcification and airway diameter, airway wall thickness, air-trapping and emphysema will be evaluated as well as clinical parameters of asthma. We will also compare those correlations from the images of healthy control subjects who performed the coronary calcium scoring CT for health checkup purpose.

Study Type

Observational

Enrollment (Actual)

72

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects who visited Allergy Clinic in SMG-SNU Boramae Medical Center for asthma or ACO

Description

Inclusion Criteria:

  • If the doctor has been diagnosed with asthma and one or more of the following criteria is met;

    1. FEV1 increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)
    2. Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)
    3. FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.

Exclusion Criteria:

  • Those who were already diagnosed and treated for coronary artery diseases.
  • Those with other structural lung diseases such as Tuberculosis destroyed lung and interstitial lung diseases
  • Those who are unable to conduct a test or questionnaire due to severe systemic illness, or cognitive dysfunction.
  • Those who are participating in other clinical trial using IND(investigational new drug) or finished other clinical trial within 30 days.
  • Those who refuse to participate in the study or withdraw the consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Asthma

If the doctor has been diagnosed with asthma and one or more of the following criteria is met;

  1. FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)
  2. Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)
  3. FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.

They can have concomittent COPD or not

Healthy control
Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
coronary calcium score
Time Frame: through study completion, an average of 1 month
coronary calcium score from coronary calcium scoring CT which, we assumed to be a surrogate marker for cardiovascular risk.
through study completion, an average of 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Min-Suk Yang, MD, SMG-SNU Boramae Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 21, 2019

Primary Completion (ACTUAL)

March 12, 2021

Study Completion (ANTICIPATED)

December 30, 2023

Study Registration Dates

First Submitted

March 29, 2018

First Submitted That Met QC Criteria

April 16, 2018

First Posted (ACTUAL)

April 26, 2018

Study Record Updates

Last Update Posted (ACTUAL)

October 1, 2021

Last Update Submitted That Met QC Criteria

September 26, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • L-2017-313

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Search Similar Trials